GROWTH
Top line decelerating.
+9.9% YoY versus +18.6% prior. 3y CAGR +11.8%.
+9.9%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
1 of 2 legendary models say BUY AMGN — but Charlie Munger disagrees.
What would legendary investors pay for AMGN?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
+9.9% YoY versus +18.6% prior. 3y CAGR +11.8%.
+9.9%Net margin 21.0% versus 12.2% prior (+8.8pp). Operating 29.1%.
21.0%P/E 24.3x — 1% above the 5y median of 24.0x. Forward 15.6x hints at EPS expansion next year.
24.3xBottom line: AMGN is rated BUY by all 2 legendary models, 34% below avg fair value $530, but earns a C sector grade (51/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
Mixed — Amgen Inc. has 89.1% ROE but D/E 9.46.
Financial story
Mixed — Amgen Inc.'s 89.1% ROE is strong, but its 9.46 debt-to-equity is elevated.
AMGN and TMO differ on P/E, ROE, and revenue growth. See the full AMGN vs TMO compare matrix.
Buffett and Munger evaluate AMGN against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
AMGN's P/E ratio is 24.5x. 5-year P/E history is in the financials tab.
1 of 2 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
AMGN's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
AMGN is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
How does AMGN compare?
See exactly where AMGN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingAMGN sits at #47 in Healthcare with a C grade (51/100).
